Nanobac Pharmaceuticals Announces New Research Study Evaluating Nanobacterial Endotoxin in Patients Undergoing Coronary Artery Angioplasty
TUESDAY, SEPTEMBER 23, 2003 10:07 AM
- BusinessWire
TAMPA, Fla., Sep 23, 2003 (BUSINESS WIRE) -- Nanobac Pharmaceuticals, Inc. (OTCPK:NNBP), announces approval of their Percutaneous Coronary Intervention (PCI) angioplasty research protocol by the Western Independent Review Board (WIRB(R), Seattle, WA). The Multi-Center PCI Study will be coordinated by the NanobacLabs Research Institute (Tampa, FL), the research subsidiary of Nanobac Pharmaceuticals, Inc., and will involve cardiologists at the University of Florida at Jacksonville, and Miami Heart Center.
The PCI study is being conducted to evaluate the presence of nanobacterial endotoxin, antigen and antibodies in patients undergoing cardiac catheterization and coronary artery angioplasty intervention. Coronary Angioplasty (PCI) involves the use of a coronary artery catheter with a balloon device. When an angioplasty catheter balloon is expanded in the coronary artery, it compresses coronary artery plaque. The purpose of the angioplasty procedure is to improve blood flow through the affected coronary artery. Calcification has been shown in other studies to comprise approximately 20% of coronary artery plaque volume. It is Nanobac's theory that the calcification in coronary artery plaque is actually calcified Nanobacterial infection within the plaque. Nanobacteria have been isolated and cultured from atherosclerotic plaque and have the unique capacity to cause calcification and inflammation in tissues.
Nanobac researchers want to answer: Does the coronary angioplasty balloon smash calcified Nanobacteria dwelling in coronary plaque? Does angioplasty cause a release of Nanobacterial endotoxin leading to inflammation and swelling in the operated coronary artery?
By testing blood samples for Nanobacteria before, during and after PCI angioplasty, Nanobac hopes to answer these questions. If the Nanobac theory is correct, nanobiotic(R) treatment before coronary intervention procedures may be able to decrease the incidence of restenosis (early closure) of coronary arteries after PCI angioplasty and/or coronary stent placement. The Study will encompass 200 patients and is designed to conclude in several months.
Nanobac Pharmaceuticals, Inc. is the leader in nanobacterial infectious disease research and development, and owns the proprietary methods of detection and treatment of nanobacterial infections. The Company's nanobacterial diagnostics and prescription nanobiotic(R) medications, demonstrated to safely and effectively treat nanobacterial infections in coronary artery heart disease and vascular disease, are available to qualified physicians.
Nanobac Pharmaceuticals, Inc. is headquartered in Tampa, Florida, U.S.A. For more information, please visit our website at: www.nanobaclabs.com.
TUESDAY, SEPTEMBER 23, 2003 10:07 AM
- BusinessWire
TAMPA, Fla., Sep 23, 2003 (BUSINESS WIRE) -- Nanobac Pharmaceuticals, Inc. (OTCPK:NNBP), announces approval of their Percutaneous Coronary Intervention (PCI) angioplasty research protocol by the Western Independent Review Board (WIRB(R), Seattle, WA). The Multi-Center PCI Study will be coordinated by the NanobacLabs Research Institute (Tampa, FL), the research subsidiary of Nanobac Pharmaceuticals, Inc., and will involve cardiologists at the University of Florida at Jacksonville, and Miami Heart Center.
The PCI study is being conducted to evaluate the presence of nanobacterial endotoxin, antigen and antibodies in patients undergoing cardiac catheterization and coronary artery angioplasty intervention. Coronary Angioplasty (PCI) involves the use of a coronary artery catheter with a balloon device. When an angioplasty catheter balloon is expanded in the coronary artery, it compresses coronary artery plaque. The purpose of the angioplasty procedure is to improve blood flow through the affected coronary artery. Calcification has been shown in other studies to comprise approximately 20% of coronary artery plaque volume. It is Nanobac's theory that the calcification in coronary artery plaque is actually calcified Nanobacterial infection within the plaque. Nanobacteria have been isolated and cultured from atherosclerotic plaque and have the unique capacity to cause calcification and inflammation in tissues.
Nanobac researchers want to answer: Does the coronary angioplasty balloon smash calcified Nanobacteria dwelling in coronary plaque? Does angioplasty cause a release of Nanobacterial endotoxin leading to inflammation and swelling in the operated coronary artery?
By testing blood samples for Nanobacteria before, during and after PCI angioplasty, Nanobac hopes to answer these questions. If the Nanobac theory is correct, nanobiotic(R) treatment before coronary intervention procedures may be able to decrease the incidence of restenosis (early closure) of coronary arteries after PCI angioplasty and/or coronary stent placement. The Study will encompass 200 patients and is designed to conclude in several months.
Nanobac Pharmaceuticals, Inc. is the leader in nanobacterial infectious disease research and development, and owns the proprietary methods of detection and treatment of nanobacterial infections. The Company's nanobacterial diagnostics and prescription nanobiotic(R) medications, demonstrated to safely and effectively treat nanobacterial infections in coronary artery heart disease and vascular disease, are available to qualified physicians.
Nanobac Pharmaceuticals, Inc. is headquartered in Tampa, Florida, U.S.A. For more information, please visit our website at: www.nanobaclabs.com.
